Financing Will Support Commercialization of HeartFlow's FFRct Analysis Technology

February 14, 2018—HeartFlow, Inc. announced the closing of Series E financing, which secured $240 million that the company will use for commercial expansion of the company's fractional flow reserve with computed tomography (FFRct) technology. The funds will also support continued technology innovation and additional clinical studies. The financing includes investments from Wellington Management, Baillie Gifford & Company, and existing investors.

The HeartFlow FFRct analysis is a noninvasive technology that creates a personalized three-dimensional model of the heart to help clinicians diagnose and treat patients with suspected coronary artery disease. According to the company, this technology has been demonstrated to reduce unnecessary and invasive diagnostic coronary angiography procedures, which can be associated with bleeding, stroke, major blood vessel damage, and other serious complications; additionally, it significantly reduces health care costs for hospitals.

In November 2017, the company announced that the Centers for Medicare & Medicaid Services finalized a new technology ambulatory payment classification for the HeartFlow FFRct technology.